Autochthonous T cells to the rescue: IL-10 directly activates tumor-resident CD8+ T cells

    loading  Checking for direct PDF access through Ovid


Successful cancer immunotherapy is thought to require de novo priming of tumor specific CD8+ T cells in lymphatic organs. Contrasting these beliefs, cancer therapy based on interleukin-10 (IL-10) results in tumor rejection without a requirement for T-cell trafficking from lymphatic organs. Rather, IL-10 directly activates autochthonous, tumor-resident CD8+ T cells.

Related Topics

    loading  Loading Related Articles